Cancer Chemotherapy: Development of Drug Resistance.

Slides:



Advertisements
Similar presentations
Cytidine analogue ALL, AML
Advertisements

Wednesday, February 15th Seth Wander
Anticancer Agents Antibiotics Classification of Antibiotics:
Chapter 56 Hematopoietic Agents 1.
Antineoplastics  W hat is Cancer ? Cancer is a disorder of cell division (leading cause of death).  C C ancers most commonly occur in: breast (♀) -
Anticancer and Chemotherapy By: Mohamed Fahad Al-Ajmi.
Copyright © 2015 Cengage Learning® Chapter 14 Antineoplastic Drugs.
Nitrogen mustards: mustard gas used first during WWI. Leukopenia and GI ulceration noted in survivors Bondage: crosslinking agents.
Familial metabolic disease Characterized by : Acute arthritis Uric stones in the kidneys Hyperuricemia.
Anticancer Therapy: Kinase Inhibitors Charles Harrell.
What is biological therapies Biological therapy is the therapeutic use of agents derived from biological sources and affecting biologic response. Also.
CANCER: ROLE OF VITAMIN C AND E IN THERAPY Gandhari, Aditi, Divya, Ankita.
Disease –Modifying Antirheumatic Drugs ( DMARDs) Slow Acting Anti-inflammatory Drugs.
MICROTEACHING Sanjeev Sharma
Dr.H-Kayalha Anesthesiologist Mucositis is a painful inflammation and ulceration of the mucous membranes of the digestive tract. Oral lesions begin as.
Cancer Chemotherapy Topics
Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 100 Basic Principles of Cancer Chemotherapy.
Cancer therapy - conventional Surgery Radiotherapy Chemotherapy Adjuvant therapies.
Cancer Drug Classes The classes of drugs currently used in the cancer clinic are  1. DNA Binding Agents (intercalating and alkylating.
PYRAMID POINTS CHAPTER 52: ANTINEOPLASTIC MEDICATIONS.
Slow Acting Anti-inflammatory Drugs. DEFINITION Drugs used to relief pain & inflammation.
Patients on Chemotherapy Dr. Feras FARARJEH. General Concepts The purpose of treating cancer with chemotherapeutic agents is to prevent cancer cells from.
II- Antimetabolites.
 Identify different options of cancer therapy.  Most cancers are treated with a combination of approaches.
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC) Victor.
By: Dr. Abdulaziz Bin Saeedan Ph.D. Department of Pharmacology E mail: P harmacology – IV PHL-425 Chapter 2: CANCER CHEMOTHERAPY:
Cancer Treatment Ashley Panakezham Rosemin Panjwani Osman Jamal Mustafa Quraishi.
Principles of Chemotherapy. Objectives At the completion of this session the participant will be able to: ◦ Define combination chemotherapy ◦ Recognize.
Chemotherapy of Tuberculosis By Prof. Azza El-Medany.
Slow Acting Anti-inflammatory Drugs ). BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSF.
Linda S. Williams / Paula D. Hopper Copyright © F.A. Davis Company Understanding Medical Surgical Nursing, 4th Edition Chapter 11 Nursing Care of.
Gout Familial metabolic disease characterized by : Acute arthritis Uric acid stones in the kidneys Hyperuricemia.
Joseph A. De Soto M.D., Ph.D., F.A.I.C.
Anthracycline induced Cardiomyopathy AM Report December AM Report December
Antineoplastic Agents and Adjunct Drugs Used in Cancer Treatment.
Microtubule inhibitors
Slide 1 Copyright © 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 44 Drugs Affecting Neoplasms.
Cytotoxic Drugs. III Dr. Yieldez Bassiouni.
1 Adverse effect of drugs Excessive Pharmacologic Effects –overdoing the therapeutic effect –Atropine –muscarinic antagonist, desired therapeutic –Effect:
© 2004 by Thomson Delmar Learning, a part of the Thomson Corporation. Fundamentals of Pharmacology for Veterinary Technicians Chapter 20 Antineoplastic.
DH206: Pharmacology CH 23: Antineoplastic Drugs Lisa Mayo, RDH, BSDH Copyright © 2011, 2007 Mosby, Inc., an affiliate of Elsevier. All rights reserved.
ERYTHROPOIESIS- STIMULATING AGENTS. Patients who are no longer able to produce enough erythropoietin in the kidneys may benefit from treatment with.
BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSIF General Features & Conditions to use antirheumatic Low doses are commonly used early in the course of the disease.
Antineoplastics Pharmacology III Practical Sessions Cairo University
Cancer Chemotherapy Dr.Azarm.  The goal of cancer treatment is eradication of cancer  If not possible shifts to palliation,amelioration and preservation.
Disease modified Anti-rheumatic drugs ( DMARD)
Cancer Heather Gates RN, BSN October 20, Core Concepts in Pharmacology, 2e By Norman Holland and Michael Patrick Adams © 2007 Pearson Education,
Anti Kanker. Cancer is the second leading cause of death Each year there are 2,300,000 deaths in the US: ◦ Heart disease 730,000 ◦ Cancer 530,000 ◦ Cerebrovascular.
CHAPTER 7 DISORDERS OF BLOOD CELLS & VESSELS. HEMATOPOIESIS Generation of blood cells Lymphoid progenitor cells = lymphocytes (WBCs) Myeloid progenitor.
Anticancer Drugs. Introduction Cancer refers to a malignant neoplasm or new growth. Cancer cells manifest uncontrolled proliferation, loss of function.
ABIRA KHAN TUMOR MARKERS & CANCER TREATMENT. TUMOR MARKERS Biological substances synthesized and released by cancer cells or produced by the host in response.
Feb. 17, 2014 Phase II, Foundation BlockAntineoplastics Faculty of Medicine, Kuwait University Prof. Saghir Akhtar RM 327, Phone: 6342
DEPARTMENT OF PHARMACEUTICS 1. Cancer In most cases, causes of cancer is multifactorial (environmental, genetic) 25% of population of U.S will be diagnosed.
Malignancy related cardiotoxicity. Cytotoxic drugs  Formation of free oxygen radicals  Induction of immunogenic reactions  Influence of the cytotoxic.
Cancer Chemotherapy.
Anti- CANCER drugs Dr. Mohammed Abd-Almoneim
Gout.
Microtubule inhibitors
Patients on Chemotherapy
Controls the Cell Cycle
Basic Principles of Cancer Chemotherapy
Anti-cancer treatment טיפול בסרטן
School of Pharmacy, University of Nizwa
بسم الله الرحمن الرحيم 1.
Chemotherapy Day 2.
Antitumour Antibiotics PHL 417
Chemotherapy Vipin Patidar
ANTIMICROTUBULES PHL 417.
OBJECTIVES To learn the mechanism of cytotoxicity and toxicity of the commonly used antimetabolites.
Presentation transcript:

Cancer Chemotherapy: Development of Drug Resistance

Probability that all tumor cells will be sensitive to a drug as a function of size of the tumor

Resistance Mechanisms  Induction of thiol containing proteins (metallothioneins) that quench the alkylators/cross-linkers. (mechlorethamine, cyclophosphamide, cisplatin)  Induction of DNA repair enzymes (cisplatin, alkylators, bleomycin, any drug that damages DNA)  Induction of glutathione transferase (catalyzes reaction of electrophiles with glutathione (alkylators)  Increased enzymatic destruction of drug (bleomycin, cytosine arabinoside)  Increased efflux of drug out of cell mediated by transporters (actinomycin D, vincristine, vinblastine, etoposide, doxorubicin, paclitaxel)  Overexpression of drug target. Gene amplification of DHFR gives resistance to methotrexate.  Mutation of drug target: Abl-kinase mutations confer resistance to imatinib (Gleevec)

Protein tyrosine kinase inhibitors: activating mutations also predict therapeutic success  Imatinib (Gleevec)  specific inhibitor of the Abl, Kit, PDGF-R kinases (active in CML and GIST)  most effective if kinase is playing a dominant role due to activating mutation  Gefitinib (Iressa)  inhibits EGF-R (not effective against the related HER2  used in non-small cell lung CA  success corelates with presence of activating mutations in EGF-R that increase its ligand sensitivity  Erlotinib (Tarceva)  targets EGF-R  approved for non-small cell lung CA  effective if tumor is dependent on EGF-R

MULTIDRUG RESISTANCE IN CANCER Three decades of multidrug-resistance research have identified a myriad of ways in which cancer cells can elude chemotherapy, and it has become apparent that resistance exists against every effective drug, even our newest agents. Michael M. Gottesman

Structures of the multi-drug resistance genes

MDR inhibitors may overcome resistance mechanism  drugs like verapamil will block the multi- drug resistance pump and could be used together with anti-tumor drugs

Toxicities common to many cancer chemotherapeutic agents 1.myelosuppression with leukopenia, thrombocytopenia, and anemia 2.mucous membrane ulceration 3.alopecia  these toxicities are caused by killing of rapidly dividing normal cells in bone marrow and epithelium

Duration and extent of bone marrow depression depends on drug

Alopecia Severe:cyclophosphamidedoxorubicinvinblastinevincristineModerate:etoposidemethotrexate Mild:bleomycinfluorouracilhydroxyurea

CDK inhibitors applied to scalp prevent alopecia from etoposide or cyclophosphamide/doxorubicin combination

Common Toxicities--continued Nausea and vomiting: direct action on CNS with some drugs: e.g. mechlorethamine, cisplatin, cyclophosphamide (delayed by about 8hr) Extravasation injury: local necrosis with many anti- cancer drugs. e.g. doxorubicin, actinomycin D vinca alkaloids (vincristine, vinblastine), mechlorethamine (not cyclophosphamide) Radiation recall: inflammatory reaction can occur months after radiation exposure drugs that form free radicals are the problem e.g. actinomycin D, doxorubicin, bleomycin, Hyperuricemia: caused by rapid tumer lysis and release of purines

Drug-specific toxicities  vincristine: peripheral neurotoxicity  cyclophosphamide: hemorrhagic cystitis  due to acrolein metabolite which is nephro and urotoxic (can be prevented with 2- mercaptoethanesulfonate--mesna)  doxorubicin: cardiomyopathy  bleomycin: pulmonary fibrosis, skin ulceration  EGFR inhibitors: skin toxicity  asparaginase: allergic reactions

Toxicity of Mitotic Inhibitors Drug Neurotox myelosuppression alopecia nausea vinblastinerare vincristine+++rare++ rare paclitaxel mild peripheral neuropathy with vincristine: numbness, weakness, loss of relexes, ataxia, cramps, neuritic pain autonomic neuropathy: abdominal pain, constipation, urinary retension, orthostatic hypotension

Doxorubicin: cardiac toxicity  Acute: electrocardiogram changes, arrhythmias within hours  Chronic: congestive heart failure (not easily treated with digitalis)  changes in mitochondria, sarcoplasmic reticulum  Ca++ATPase activity inhibited  rapid decrease in CARP (cardiac ankyrin repeat protein)  slow decrease in heart specific structural proteins and ATP generating enzymes  cellular degeneration observed in ~20% of pt  decreased left ventricular ejection fraction (more evident while exercising)  Risk factors: previous chest radiation, hypertension, combination with other cardiotoxic drugs (herceptin)

Detecting cardiac toxicity in patients after doxorubicin treatment

Bleomycin toxicity  lungs  progressive fibrosis, chronic interstitial inflammation  450mg 10%  risk factors: age, emphysema, renal failure, previous radiotherapy to the chest, oxygen administration  skin  ~50% pts have erythema, peeling, ulceration  systemic toxicity: ~1% of lymphoma pts develop hyperthermia, hypotension, cardiovascular collapse (release of endogenous pyrogens?)  both lungs and skin have low levels of bleomycin hydrolase and this may be why they are so sensitive to the drug

EGFR inhibitors cause skin toxicity

Herceptin cardiac toxicity

Efforts to limit toxicity  allopurinol: treat hyperuricemia, uric acid precipitates in kidney  hydration/diuretics: e.g. reduce cisplatin nephrotoxicity  leucovorin: limit toxicity of high dose methotrexate  hematopoietic growth factors: restore bone marrow derived cells (RBCs, lymphocytes, granulocytes, platelets)

Allopurinol inhibits zanthine oxidase and prevents hyperuricemia during chemotherapy

Hematopoietic growth factors  erythropoietin: stimulates RBC formation  G-CSF (filgrastim): stimulates neutrophils and eosinophils  GM-CSF (sargramostim): stimulates neutrophils, monocyte/macrophage  thrombopoietin: stimulates platelet formation  benefits: allows high dose chemotherapy with much less toxicity, reduced risk of infection

Goodman & Gilman Hematopoietic growth factors